Parisi Gray Wealth Management Increases Position in Eli Lilly and Company (NYSE:LLY)

Parisi Gray Wealth Management boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 58.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,423 shares of the company’s stock after purchasing an additional 2,010 shares during the period. Eli Lilly and Company makes up approximately 1.3% of Parisi Gray Wealth Management’s portfolio, making the stock its 19th biggest holding. Parisi Gray Wealth Management’s holdings in Eli Lilly and Company were worth $3,161,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of LLY. Thompson Investment Management Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter worth $27,000. Retirement Group LLC lifted its holdings in Eli Lilly and Company by 159.1% during the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after buying an additional 35 shares during the last quarter. Cornerstone Planning Group LLC bought a new position in Eli Lilly and Company during the second quarter worth $33,000. Legacy Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth $35,000. Finally, Optiver Holding B.V. bought a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at about $36,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded up $12.24 during trading on Thursday, reaching $790.42. 480,242 shares of the company’s stock were exchanged, compared to its average volume of 3,188,776. Eli Lilly and Company has a fifty-two week low of $334.58 and a fifty-two week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The business has a 50 day moving average price of $727.96 and a 200 day moving average price of $636.01. The company has a market capitalization of $751.03 billion, a P/E ratio of 134.26, a PEG ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the company earned $2.09 earnings per share. The business’s revenue was up 28.1% compared to the same quarter last year. As a group, analysts predict that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Barclays upped their target price on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 20th. BMO Capital Markets upped their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $689.52.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 14,388 shares of the company’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares in the company, valued at approximately $62,873,217,098.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 195,055 shares of company stock worth $125,254,657. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.